Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 12/20 | 0.45 |
| ▸ | GLP1R | P43220 | 3/20 | 0.42 |
| ▸ | SCTR | P47872 | 1/20 | 0.42 |
| ▸ | CTSD | P07339 | 1/20 | 0.42 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.39 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.39 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.39 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.39 |
| ▸ | REN | P00797 | 1/20 | 0.39 |
| ▸ | CALCRL | Q16602 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30799847 | 0.91 | BACE1 (0.52) | BACE1CTSDCALCRL | |
| SCHEMBL30799665 | 0.89 | BACE1 (0.51) | BACE1CTSDSLC6A2 | |
| SCHEMBL30799588 | 0.88 | BACE1 (0.51) | BACE1CTSDOPRM1OPRD1OPRK1 | |
| SCHEMBL30799567 | 0.87 | BACE1 (0.48) | BACE1CTSDOPRM1OPRD1OPRK1 | |
| SCHEMBL30799707 | 0.86 | BACE1 (0.53) | BACE1CTSDOPRM1OPRD1OPRK1 | |
| SCHEMBL30799513 | 0.82 | BACE1 (0.49) | BACE1CTSDOPRM1OPRD1CALCRL | |
| SCHEMBL30799759 | 0.82 | BACE1 (0.52) | BACE1CTSDOPRM1OPRD1OPRK1 | |
| SCHEMBL31181265 | 0.82 | GLP1R (0.42) | GLP1RSCTROPRM1OPRD1OPRK1 | |
| SCHEMBL30261968 | 0.82 | BACE1 (0.39) | BACE1CTSDSLC6A2 | |
| SCHEMBL30799841 | 0.82 | BACE1 (0.53) | BACE1CTSDOPRM1OPRD1OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240116985-A1 | STAPLED PEPTIDES AND METHODS THEREOF | PARABILIS MEDICINES, INC. | 2024-04-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240116985-A1 | STAPLED PEPTIDES AND METHODS THEREOF | CTNNB1, APC, CTNNA1 | BACE1 10/4885GLP1R 21/4885SCTR 143/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.